U.S. Capital Wealth Advisors LLC Has $9.34 Million Position in Eli Lilly and Company $LLY

Key Points

• U.S. Capital Wealth Advisors LLC increased its holdings in Eli Lilly by 38.7% in the second quarter, owning nearly 12,000 shares valued at approximately $9.34 million.
• Analyst ratings for Eli Lilly have fluctuated, with Cantor Fitzgerald reducing their target price from $975 to $825, while another firm downgraded its rating from "strong-buy" to "buy."
• CEO David A. Ricks and Director Jamere Jackson both made significant stock purchases, with Ricks acquiring 1,632 shares valued at over $1 million, indicating insider confidence in the company's future.

U.S. Capital Wealth Advisors LLC increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 38.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,987 shares of the company's stock after purchasing an additional 3,342 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $9,344,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. WestEnd Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company during the first quarter valued at $27,000. Citizens National Bank Trust Department raised its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the first quarter valued at $40,000. Finally, TD Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after purchasing an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $3.33 during trading hours on Monday, hitting $755.32. The company's stock had a trading volume of 2,524,436 shares, compared to its average volume of 3,388,311. The business's 50-day moving average is $737.49 and its two-hundred day moving average is $769.01. The company has a market capitalization of $714.88 billion, a PE ratio of 49.37, a PEG ratio of 1.05 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $939.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company earned $3.92 EPS. The firm's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on LLY shares. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their target price for the stock from $675.00 to $700.00 in a research note on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.